Browsing Tag
Female Testosterone MDTS
1 post
Acrux (ASX: ACR) secures clearer FDA Phase III pathway for female testosterone treatment
Acrux has received formal FDA feedback defining the Phase III clinical development requirements for Female Testosterone MDTS, potentially supporting a future United States registration application while leaving trial funding, safety evidence and commercial partnerships unresolved.